Key result
Maternal EV71 neutralizing antibodies were present in 46% of neonates at birth but declined to undetectable levels by 6 months of age.
Cohort (n=201)
Yes
Answers are grounded in this paper and cite their sources.
Maternal neutralizing antibodies against EV71 decline to undetectable levels by 6 months of age, suggesting that EV71 vaccines should target infants under 6 months.
Background: Clinical spectrum of EV71 infection ranges from mild hand-foot-mouth disease (HFMD) to severe cases with central nervous system and cardiopulmonary involvements. In 1998, Taiwan suffered a nation-wide EV71 epidemic with 405 reported severe cases and 78 fatal cases. Since then, EV71 has been endemic in Taiwan and development of EV71 vaccines has become a national priority. This cohort study was designed to understand decline of maternal EV71 neutralizing antibody titers and age-specific incidence rates of EV71 infection in Taiwan, which will be crucial for designing efficacy trials of EV71 vaccines. Methods: This study is a prospective longitudinal cohort study and was approved by the Institutional Review Boards in CGMH and NHRI. Pregnant women having prenatal exams were invited to participate. Sera were collected from participating mother/baby for measuring EV71 neutralizing antibody titers in the following schedules: last trimester from mother, umbilical cord blood at birth, and children at 6, 12, 24, 36, and 48 months old. Results: The recruitment started in June 2006. By January 2008, 201 longitudinal serum specimens collected from mothers, neonates, and 6-month-old babies (one mother delivered twins) have been measured with EV71 neutralizing antibody titers. The seropositive rates (percentage of antibody titer ≥ 1:8) in mothers, neonates, and 6-month-old babies were 61%(122/201), 46%(93/202), and 0%(0/202), respectively. Geometric mean titers (95% confidence intervals) of serum EV71 antibody in mothers and neonates were 10.2 (8.7, 11.5) and 8.5 (7.4, 9.7), respectively. Conclusions: In northern Taiwan, only 46% of neonates have protective antibody against EV71 and these maternal antibody titers have declined to undetectable level (<8) by 6 months of age. Historical data in the 1998 epidemic also showed that infants under 1 year old had the highest risk of severe EV71 infection. Therefore, development of EV71 vaccines in Taiwan should target infants under 6 months old.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2008) conducted a cohort in EV71 infection (n=201). Maternal EV71 neutralizing antibody was evaluated on Seropositive rates (antibody titer ≥ 1:8) of EV71 neutralizing antibody. Maternal EV71 neutralizing antibodies were present in 46% of neonates at birth but declined to undetectable levels by 6 months of age.
Synapse has enriched 10 related papers. Consider them for comparative context: